Concepedia

Ros1 Oncogene

ROS1 Oncogene is a receptor tyrosine kinase oncogene that arises from chromosomal rearrangements leading to constitutive kinase activation and is implicated in the pathogenesis of certain cancers, notably non-small cell lung cancer.

409

Publications

30K

Citations

3.1K

Authors

1K

Institutions

Publications per year

2017–2026

252

Parents

Publications

409

Crizotinib in <i>ROS1</i>-Rearranged Non–Small-Cell Lung Cancer

Alice T. Shaw, Sai‐Hong Ignatius Ou, Yung‐Jue Bang et al. · New England Journal of Medicine · 2014 · 2K citations

, , +17

<i>ROS1</i> Rearrangements Define a Unique Molecular Class of Lung Cancers

Kristin Bergethon, Alice T. Shaw, Sai‐Hong Ignatius Ou et al. · Journal of Clinical Oncology · 2012 · 1.6K citations · Full text

, , +16

RET, ROS1 and ALK fusions in lung cancer

Kengo Takeuchi, Manabu Soda, Yuki Togashi et al. · Nature Medicine · 2012 · 1.3K citations

, , +14

Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial

Alice T. Shaw, Enriqueta Felip, Todd M. Bauer et al. · The Lancet Oncology · 2017 · 649 citations · Full text

, , +14

Discovery of (10 <i>R</i> )-7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro- <i>2H</i> -8,4-(metheno)pyrazolo[4,3- <i>h</i> ][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a Macrocyclic Inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-ros Oncogene 1 (ROS1) with Preclinical Brain Exposure and Broad-Spectrum Potency against ALK-Resistant Mutations

Ted W. Johnson, Paul Richardson, Simon Bailey et al. · Journal of Medicinal Chemistry · 2014 · 585 citations · Full text

, , +16

1–5 of 409

Authors

3.1K

  1. RC
    Robert C. Doebele

    University of Colorado Denver, United States

    32 publications · 5.1K citations

    24

    h-index

  2. AT
    Alice T. Shaw

    Massachusetts General Hospital, United States

    32 publications · 7.8K citations

    22

    h-index

  3. AD
    Alexander Drilon

    Memorial Sloan Kettering Cancer Center, United States

    26 publications · 2.2K citations

    19

    h-index

  4. SI
    Sai‐Hong Ignatius Ou

    University of California, Irvine, United States

    21 publications · 5K citations

    18

    h-index

  5. DR
    D. Ross Camidge

    University of Colorado Denver, United States

    22 publications · 3.9K citations

    17

    h-index

1–5 of 3.1K

Institutions

1K

  1. Memorial Sloan Kettering Cancer Center

    New York, United States

    30 h-index

    119 publications

    14.8K citations

  2. Massachusetts General Hospital

    Boston, United States

    27 h-index

    187 publications

    38.7K citations

  3. University of Colorado Denver

    Denver, United States

    23 h-index

    127 publications

    14.5K citations

  4. Pfizer (United States)

    New York, United States

    22 h-index

    183 publications

    53.3K citations

  5. University of Colorado Anschutz Medical Campus

    Aurora, United States

    21 h-index

    111 publications

    22.7K citations

  6. University of California, Irvine

    Irvine, United States

    18 h-index

    32 publications

    4.3K citations

  7. Inserm

    Paris, France

    18 h-index

    76 publications

    4.4K citations

  8. Harvard University

    Cambridge, United States

    18 h-index

    122 publications

    14.3K citations

1–8 of 1K

Venues

  1. Journal of Thoracic Oncology

    33 publications · 2.3K citations

    24

    h-index

  2. Lung Cancer

    25 publications · 1.2K citations

    19

    h-index

  3. Journal of Clinical Oncology

    24 publications · 3.4K citations

    17

    h-index

  4. Clinical Cancer Research

    14 publications · 2.5K citations

    14

    h-index

  5. Oncotarget

    13 publications · 647 citations

    13

    h-index

1–5